Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Alcindor

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
Annals of Surgical Oncology|July 16, 2014
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinomaMonisha Sudarshan, Thierry Alcindor, Steven Ades, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|July 14, 2023
Survival and perioperative outcomes of octo- and nonagenarians with resectable esophageal carcinomaNabeel Ahmed, James Tankel, Jamil Asselah, et al.
JCO Precision Oncology|July 6, 2026
Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair DeficiencyThierry Alcindor, David J Papke, Vinayak Venkataraman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2024
Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue SarcomaGregory M Cote, Candace L Haddox, Edwin Choy, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|December 24, 2019
A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancerVilma Pacheco-Barcia, Rebeca Mondéjar Solís, Talya France, et al.
Pancreas|May 16, 2019
A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic CancerVilma Pacheco-Barcia, Rebeca Mondéjar Solís, Talya France, et al.
The American Journal of Surgical Pathology|June 12, 2026
Clinicopathologic Study of 39 Mismatch Repair-deficient Sarcomas Demonstrates Recurrent Histologic Patterns and Supports Universal Screening of Pleomorphic Rhabdomyosarcoma, Uterine Leiomyosarcoma, and Undifferentiated and Unclassified SarcomasIgor Odintsov, Jonathan A Nowak, Esther Baranov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus DacarbazineGeorge D Demetri, Patrick Schöffski, Giovanni Grignani, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|April 4, 2024
Survival in esophageal cancer with nonregional lymphadenopathy: a propensity score-matched analysisJames Tankel, Rawan Sakalla, Neyla Boukhili, et al.
International Journal of Molecular Sciences|January 11, 2024
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line TherapyKaren Gambaro, Maud Marques, Suzan McNamara, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Annals of Surgical Oncology|July 16, 2014
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinomaMonisha Sudarshan, Thierry Alcindor, Steven Ades, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|July 14, 2023
Survival and perioperative outcomes of octo- and nonagenarians with resectable esophageal carcinomaNabeel Ahmed, James Tankel, Jamil Asselah, et al.
JCO Precision Oncology|July 6, 2026
Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair DeficiencyThierry Alcindor, David J Papke, Vinayak Venkataraman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2024
Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue SarcomaGregory M Cote, Candace L Haddox, Edwin Choy, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|December 24, 2019
A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancerVilma Pacheco-Barcia, Rebeca Mondéjar Solís, Talya France, et al.
Pancreas|May 16, 2019
A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic CancerVilma Pacheco-Barcia, Rebeca Mondéjar Solís, Talya France, et al.
The American Journal of Surgical Pathology|June 12, 2026
Clinicopathologic Study of 39 Mismatch Repair-deficient Sarcomas Demonstrates Recurrent Histologic Patterns and Supports Universal Screening of Pleomorphic Rhabdomyosarcoma, Uterine Leiomyosarcoma, and Undifferentiated and Unclassified SarcomasIgor Odintsov, Jonathan A Nowak, Esther Baranov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus DacarbazineGeorge D Demetri, Patrick Schöffski, Giovanni Grignani, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|April 4, 2024
Survival in esophageal cancer with nonregional lymphadenopathy: a propensity score-matched analysisJames Tankel, Rawan Sakalla, Neyla Boukhili, et al.
International Journal of Molecular Sciences|January 11, 2024
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line TherapyKaren Gambaro, Maud Marques, Suzan McNamara, et al.
Pageof 7